Vertex Pharmaceuticals has patented a method for producing ß cells and their precursors using Wnt signaling inhibitors or PKC activators. The patent also covers in vitro cultures of these cells, treatment methods for high blood sugar diseases, and devices for encapsulating the cells. GlobalData’s report on Vertex Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vertex Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Vertex Pharmaceuticals's grant share as of May 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Production of ß cells for treating high blood sugar levels
A recently granted patent (Publication Number: US11999971B2) discloses an in vitro composition comprising a population of cells derived from stem cells, showcasing specific characteristics. The composition includes cells expressing NKX6.1 and ISL1, cells expressing ISL1 but not NKX6.1, and cells expressing ARX and glucagon in varying percentages. Additionally, the composition contains genetically modified cells and can be utilized in one or more cell clusters. The patent also covers the use of inhibitors and activators in the composition to enhance its functionality.
Furthermore, the patent details the genetic modifications in the cells to reduce immune responses, including disruptions in genes encoding beta-2-microglobulin and HLA proteins. The composition is designed for potential implantation into human subjects and the levels of specific markers like NKX6.1 and ISL1 can be determined using immunocytochemistry or flow cytometry. The inclusion of various inhibitors and activators in the composition further highlights the versatility and potential applications of this innovative in vitro cell population.
To know more about GlobalData’s detailed insights on Vertex Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
